MMIT Reality Check on Bipolar Disorder (July 2021)

According to our recent payer coverage analysis for bipolar disorder treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for bipolar disorder treatments shows that under the pharmacy benefit, about 21% of the lives under commercial formularies are covered with utilization management restrictions.

Trends: In May 2021, the FDA approved Alkermes plc’s Lybalvi (olanzapine and samidorphan) for adults with schizophrenia and for adults with bipolar I disorder, for the acute treatment of manic or mixed episodes as monotherapy and as adjunct to lithium or valproate and as a maintenance monotherapy treatment.

0 Comments

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/10/WordPress-Featured-Image-reality-checl-psoriasis.jpg
October 22

MMIT Reality Check on Psoriasis

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/10/WordPress-Featured-Image-reality-check-hemophilia.jpg
October 15

MMIT Reality Check on Hemophilia A (Factor VIII) (Oct 2021)

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/10/wordpress-featured-image-reality-check-diffuse-large-b-cell-lymphoma.jpg
October 8

MMIT Reality Check on Diffuse Large B-Cell Lymphoma (Oct 2021)

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today